Latest Articles and Analysis

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

Federal executive actions protect LGBTQ people as states restrict gender-affirming care and trans rights.

CANN roundtable examines COVID-19 impacts on public health advocacy, Medicaid expansion, and HIV programs.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

CDC updates STI treatment guidelines; ACIP recommends universal adult HBV vaccination and HPV catch-up.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Analyzes CMS marketplace rule changes and Medicaid expansion risks as pandemic emergency declarations end.

Analyzes Biden health policy priorities including drug pricing reform and Medicare expansion.

Post-PHE planning for Medicaid redetermination: extended timelines and navigator support for safety net care.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

Examines CMS's rebate rule on copay accumulator programs that block patient assistance from counting toward deductibles.

Restrictive Medicaid policies limit HCV treatment access through fibrosis restrictions and sobriety requirements.